SCHEMBL24596365

SCHEMBL24596365

CCOC(=O)c1ncoc1-c1ccc(C(F)(F)F)nc1Nc1cccnc1C1CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.37
SYK P43405 2/20 0.37
TGFBR1 P36897 1/20 0.36
HCRTR1 O43613 3/20 0.34
TDP2 O95551 2/20 0.33
P2RY1 P47900 1/20 0.33
MAT2A P31153 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
GRM5 P41594 1/20 0.33
MAPT P10636 1/20 0.33
IGF1R P08069 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CACNA1B Q00975 1/20 0.32
APBA1 Q02410 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29790055 1.00 BRD4 (0.37) BRD4SYKTGFBR1HCRTR1TDP2
SCHEMBL29790062 0.88 TGFBR1 (0.41) BRD4SYKTGFBR1TDP2P2RY1
SCHEMBL26631694 0.88 BRD4 (0.41) BRD4SYKTGFBR1TDP2P2RY1
SCHEMBL24596361 0.88 TGFBR1 (0.41) BRD4SYKTGFBR1TDP2P2RY1
SCHEMBL29789898 0.85 MAPT (0.38) BRD4TRPV1MAPTCACNA1BAPBA1
SCHEMBL24596290 0.85 MAPT (0.38) BRD4TRPV1MAPTCACNA1BAPBA1
SCHEMBL24596387 0.83 MAPT (0.41) SYKMAPTIGF1RNPC1RAB9A
SCHEMBL29789936 0.83 MAPT (0.41) SYKMAPTIGF1RNPC1RAB9A
SCHEMBL24596245 0.81 SIRT5 (0.39) BRD4SYKTGFBR1NPC1RAB9A
SCHEMBL29790079 0.81 SIRT5 (0.39) BRD4SYKTGFBR1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A BRD4 3607/4885SYK 4805/4885TGFBR1 3478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.